Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Zosano Pharma Corporation (ZSAN)

NEW YORK, April 14, 2016

This investigation concerns whether Zosano and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act"). 

The investigation concerns: (1) Zosano's SEC filings in connection with the Company's January 27, 2015 Initial Public Offering ("IPO") may have contained misleading information or untrue statements, (2) and, whether Zosano sufficiently related the risks and viability of its lead osteoporosis drug program, ZP-PTH, and Zosano's partnership with Eli Lily and Co. Following the news of the suspected disappointment of the ZP-PTH reaching commercial viability, Zosano stock dropped from the IPO price of $11 per share to close at $2.35 per share on April 7, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Zosano, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!zsan/de2sa. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com